CN1077797C - Chinese medicine powder preparation for curing leukemia - Google Patents

Chinese medicine powder preparation for curing leukemia Download PDF

Info

Publication number
CN1077797C
CN1077797C CN99124959A CN99124959A CN1077797C CN 1077797 C CN1077797 C CN 1077797C CN 99124959 A CN99124959 A CN 99124959A CN 99124959 A CN99124959 A CN 99124959A CN 1077797 C CN1077797 C CN 1077797C
Authority
CN
China
Prior art keywords
grams
parts
radix
chinese medicine
rhizoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN99124959A
Other languages
Chinese (zh)
Other versions
CN1262955A (en
Inventor
董伍信
刘国奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN99124959A priority Critical patent/CN1077797C/en
Publication of CN1262955A publication Critical patent/CN1262955A/en
Application granted granted Critical
Publication of CN1077797C publication Critical patent/CN1077797C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to traditional Chinese medicinal powder for treating leukemia, which can be used for treating nosohemias, such as aplastic anemia, etc. The medicinal powder is made from bupleurum root, perilla leaf, fineleaf schizonepeta herb, largehead atractylodes rhizome, charred triplet, tuckahoe, ophiopogon, white peony alba, angelica, gardenia, scutellaria, pangolin scale, turtle shell, lower shell, oriental wormwood, common anemarrhena rhizome, wolfberry bark, licorice, imperatae rhizoma and eucommia bark. The present invention has the advantages of scientific and reasonable compatibility, convenient taking, low cost, good therapeutic effect, no side effect and good economic and social benefit.

Description

Treat leukemic Chinese medicine powder
The present invention relates to a kind of leukemic Chinese medicine powder (claiming Bai Xuekang again) for the treatment of clinically, also can be used for aplastic anemia.
Leukemia is a kind of difficult disease of common pilosity, claims leukemia again.The leukemic medicine of treatment is a lot of at present, but its curative effect is not good enough.Treat leukemic best approach is to carry out bone marrow transplantation for this reason, but its expense costliness, and the difficult again selection of suitable bone marrow, therefore at present still based on Drug therapy, and the dual-purpose chemotherapy.But all curative effect is not good enough, and side effect is arranged, and particularly takes Western medicine and chemotherapy.Therefore, how to adopt medicine effectively to treat leukemia and be still the problem that people are concerned about.
Purpose of the present invention just provides the leukemic Chinese medicine powder of a kind of treatment, to solve the leukemic medication problem of treatment conveniently and effectively.
The object of the present invention is achieved like this, according to the Chinese medicine and pharmacy principle, leukemia belongs to exopathogen stream internal organs, the infringement vital organs of the human body, and hemopoietic function goes down, leukocyte infinitely increases or reduces, make viscera function imbalance, that the health invasion and attack form is hemorrhage, deteriorated blood, warm blood, returns pyretic toxicity to send out a class category, it is purpose that its treatment is adopted to effect a permanent cure, treating both the principal and secondary aspects of a disease.According to the Chinese materia medica principle, adopt Radix Bupleuri, Folium Perillae, Herba Schizonepetae, the Rhizoma Atractylodis Macrocephalae, JIAOSANXIAN (Fructus Crataegi, Fructus Hordei Germinatus, Massa Medicata Fermentata), Poria, Radix Ophiopogonis, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Fructus Gardeniae, Radix Scutellariae, Squama Manis, Carapax Trionycis, Carapax et Plastrum Testudinis (Carapax et Plastrum Testudinis), Herba Artemisiae Scopariae, the Rhizoma Anemarrhenae, Cortex Lycii, Radix Glycyrrhizae, Rhizoma Imperatae, the Cortex Eucommiae to make Chinese medicine powder and get final product.
Compatibility of the present invention is scientific and reasonable, abundant raw materials, and taking convenience safety has no side effect, and good effect is easy to apply, and can be the treatment leukemia and makes positive contribution
Below in conjunction with concrete condition and embodiment the present invention is elaborated.
According to aforementioned medicine requirement, the present invention adopts by weight 15 parts of Radix Bupleuri, 6 parts of Folium Perillae, 9 parts of Herba Schizonepetae, 9 parts of the Rhizoma Atractylodis Macrocephalaes, each 9 parts of JIAOSANXIAN (Fructus Crataegi, Fructus Hordei Germinatus, Massa Medicata Fermentata), 15 parts in Poria, 9 parts of Radix Ophiopogonis, 15 parts of the Radix Paeoniae Albas, 15 parts of Radix Angelicae Sinensis, 9 parts of Fructus Gardeniaees, 9 parts of Radix Scutellariae, 6 parts of Squama Maniss, goes up 9 parts of first, 9 parts of Carapax et Plastrum Testudinis, 9 parts of Herba Artemisiae Scopariaes, 9 parts of the Rhizoma Anemarrhenaes, 9 parts of Cortex Lycii, 9 parts in Radix Glycyrrhizae, 6 parts of Rhizoma Imperataes, the Cortex Eucommiae are formed medicine for 9 parts, and it is ground into Chinese medicine part gets final product.
As restraining juice by adult's dose 216 on the one, it is Radix Bupleuri 15 grams, Folium Perillae 6 grams, Herba Schizonepetae 9 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, each 9 gram of JIAOSANXIAN (Fructus Crataegi, Fructus Hordei Germinatus, Massa Medicata Fermentata), Poria 15 grams, Radix Ophiopogonis 9 grams, the Radix Paeoniae Alba 15 grams, Radix Angelicae Sinensis 15 grams, Herba Artemisiae Scopariae 9 grams, the Rhizoma Anemarrhenae 9 grams, Cortex Lycii 9 grams, Radix Glycyrrhizae 6 grams, Rhizoma Imperatae 6 grams, the Cortex Eucommiae 9 grams, Fructus Gardeniae 9 grams, Radix Scutellariae 15 grams, Squama Manis 6 grams that its Chinese medicine powder constitutes, go up first 9 grams, Carapax et Plastrum Testudinis 9 grams are formed, be crushed and screened into powder through size reduction machinery, restrain the medicated powder decoctions with 216 when taking, the decocting secondary, sooner or later respectively once, each 106 grams, the child can be cut down according to the circumstance on request in this way.If need other dosage, can connect the compatibility requirement, enlarge or dwindle.
The Chinese medicine powder of making by said medicine, as everybody knows, its symptom of leukemia show as more dizziness, ear toot, unable, heating and with hemopoietic function go down, leukocyte infinitely increases or reduce, want to cure this disease, must make hematopoietic function recovery, want to make hematopoietic function recovery, must effect a radical cure the cause of disease, get rid of evils and set upright, and all medicines of its compatibility head it off just in time.In its compatibility, Radix Bupleuri, Folium Perillae, Herba Schizonepetae can prevent superfunction, and exopathogen can not be invaded; The Rhizoma Atractylodis Macrocephalae, JIAOSANXIAN (Fructus Crataegi, Fructus Hordei Germinatus, Massa Medicata Fermentata), Poria can be built taste poker, water channel, Shui Gu, and precise and tiny energyization is given birth to, angry blood; Radix Ophiopogonis, the Radix Paeoniae Alba, Fructus Gardeniae, Radix Scutellariae removing heat from blood, hemopoietic; Squama Manis, Carapax et Plastrum Testudinis, last first depressed liver-energy dispersing and QI regulating; The Radix Angelicae Sinensis blood circulation promoting and blood stasis dispelling, the catharsis function of promotion liver; Herba Artemisiae Scopariae, Radix Glycyrrhizae are annotated jaundice diuretic, antiviral; The Rhizoma Anemarrhenae, Cortex Lycii, the Cortex Eucommiae, Rhizoma Imperatae energy promoting the production of body fluid to quench thirst, cloudy now tonifying YANG, removing heat from blood are gone into kidney, main bone is given birth to marrow.The reasonable cooperation of above-mentioned all medicines can make hemopoietic function, hemopoietic functional rehabilitation normal effectively, increases the resistance against diseases of body, controls leukocytic unlimited increase or minimizing, thereby hematopoietic disorders is removed, and sick body is rehabilitated.Clinical practice has also proved this point.
Through in recent years the situation of 80 routine leukemia human therapies being seen, wherein male 48 people, woman 32 people, age was taken 216 grams every day at 14-68 years old, each decoction 108 gram of per morning and evening, 32 days is a course of treatment, take medicine 1-2 the course of treatment sx, 4-6 the course of treatment transference cure, bone marrow check half a year transfers to normally to half.Took after a course of treatment drug withdrawal 3-7 days at every turn, and continued again to take, after the remission, reduce by half to take and kept curative effect in 3 months.
The present invention also is effectively applied to aplastic anemia, as to 32 people's clinical practices, and wherein male 16 people, women 16 people, the age is 8-68 years old, and consumption is grams every days 216, divides the secondary usefulness that is decocted in water for oral dose, and each 108 grams have all been obtained satisfied effect, and seeing has 1.
Table 1 (leukemia and aplastic anemia joint account)
Group The example number Produce effects Effectively Invalid Total effective rate
Experimental group 112 80 25 7 94%
Matched group 112 35 38 39 65.2%
Experimental group is taken Chinese medicine powder, and matched group is taken Western medicine, and Western medicine includes vincristin, prednisone, gentle red mould etc., finds out that obviously experimental group is better than matched group from table.
With regard to its clinical symptoms, obvious difference is arranged all before and after the treatment.
Table 2 is taken Chinese medicine powder and chemotherapy contrast
Experimental group Insomnia Emit through often feeling The joint headache Fever Face storehouse color is white Hyperhidrosis Dizzy
Before the treatment 112 112 55 112 87 63 76
After the treatment Disappear 80 99 45 102 65 57 58
Take a turn for the better 22 13 8 10 22 6 14
Invalid 10 0 2 0 0 0 4
Control changing according to learning the treatment group Before the treatment 112 84 43 94 76 65 78
After the treatment Disappear 84 26 28 30 22 48 12
Take a turn for the better 38 30 11 42 38 11 63
Invalid 41 13 4 22 16 6 3
It can be seen from the table, it is respond well to take medicated powder of the present invention, and obviously is better than matched group.Through laboratory examination, with before and after the Chinese medicine powder treatment significant difference being arranged, show that sb.'s illness took a favorable turn, see Table 3,4.
Blood picture synopsis around before and after the treatment of table 3 disorders of blood
Project CR standard (alleviating standard fully) Before the treatment After the treatment
HB (hemoglobin) 100g/L (man) 90g/L (woman) (child) 50 110
WBC (numeration of leukocyte) <10×10 9/L 22×10 9/L 7×10 9/L
Neutrophilic granulocyte ≥1.5×10 9/L 1.0×10 9/L 4×10 9/L
Lymphocyte <0.4 0.55 0.28
Platelet ≥100×10 9/L 70×10 9/L 105×10 9/L
Peripheral blood divides the apoplexy due to endogenous wind leukaemia number Do not have Do not have
Medullary cell is checked synopsis (112 count for each person) before and after table 4 treatment
The cell title Normal value Standard deviation Before the treatment After the treatment
Slow grain Anxious grain Aplastic anemia
The granulocyte system Myeloblast 0.64 0.33 2.4 0.63
Promyelocyte 1.57 0.6 0.4 6.2 1 1.6
Neutrophilic granulocyte Middle children 6.49 2.04 15.2 9.2 6.98
Evening is young 7.9 1.97 23.2 8.6 4 8.8
Dried shape nuclear 23.72 3.5 44.4 6.2 26.05
Leaflet nuclear 9.41 2.92 9 8.8 9.25
Eosinophilic granulocyte Middle children 0.38 0.23 0.4 0.3
Evening is young 0.49 0.32 1 0.39
Dried shape nuclear 1.25 0.61 0.4 1.05
Leaflet nuclear 0.86 0.61 1.6 0.76
Basophil Middle children 0.02 0.05 0.02
Evening is young 0.06 0.07 0.2 0.05
Dried shape nuclear 0.1 0.09 0.8 0.09
Leaflet nuclear 0.03 0.05 0.4 0.03
The erythrocyte system Pronormoblast 0.57 0.3 0.2 0.6 0.2
Basophilic erythroblast 0.29 0.41 0.2 1.4 0.27
Polychromatophilic erythroblast 7.41 1.91 0.6 21 4 70
Normoblast 10.75 2.36 19.8 11 7.68
The lymphocyte system Lymphoblast 0.05 0.09 0.02
Inmature lymphocyte 0.47 0.84 0.12
Lymphocyte 22.78 7.04 0.8 10.8 59 02.8
Unusual lymphocyte
The mononuclear cell system Monoblast 0.01 0.04 0.01
Inmature mononuclear cell 0.14 0.19 0.17
Mononuclear cell 3 0.88 0.4 4.8 2 3.49
The plasma cell system Plasmablast 0.004 0.02
Proplasmacyte 0.104 0.16
Plasma cell 0.71 0.42 0.2 1 0.68
Other cell Skein cell 0.16 0.21 0.6 2 0.27
Endotheliocyte 0.05 0.09
Phagocyte 0.03 0.09 0.07
Adipose cell 0.003 0.02
Tissue is bitten the alkali cell 0.03 0.09 0.03
Tissue is bitten sour cell 0.004 0.03
The not clear-cells of classifying 0.15 0.03 0.17
Remarks: This table is with reference to Henan Medical Univ.'s one attached institute cytoscopy normal value standard
Composition of medicine of the present invention also can not become the direct decoction of powder, also can be processed into capsule or tablet and other dosage forms.
Clearly show that by above-mentioned situation the present invention comprises chemotherapeutic treatment leukemia, having greatly improved property of aplastic anemia with existing medicine, have one's own knack that it is applied and must make creative contribution for the treatment hematopathy.

Claims (2)

1, the leukemic Chinese medicine powder of a kind of treatment is characterized in that this Chinese medicine powder is to be made for 9 parts by 15 parts of Radix Bupleuri, 6 parts of Folium Perillae, 9 parts of Herba Schizonepetae, 9 parts of the Rhizoma Atractylodis Macrocephalaes, each 9 parts of JIAOSANXIAN (Fructus Crataegi, Fructus Hordei Germinatus, Massa Medicata Fermentata), 15 parts in Poria, 9 parts of Radix Ophiopogonis, 15 parts of the Radix Paeoniae Albas, 15 parts of Radix Angelicae Sinensis, 9 parts of Fructus Gardeniaees, 9 parts of Radix Scutellariaes, 6 parts of Squama Maniss, 9 parts of last first, 9 parts of Carapax et Plastrum Testudinis, 9 parts of Herba Artemisiae Scopariaes, 9 parts of the Rhizoma Anemarrhenaes, 9 parts of Cortex Lycii, 9 parts in Radix Glycyrrhizae, 6 parts of Rhizoma Imperataes, the Cortex Eucommiae.
2, the leukemic Chinese medicine powder of treatment according to claim 1, the Chinese medicine powder of it is characterized in that Radix Bupleuri 15 grams, Folium Perillae 6 grams, Herba Schizonepetae 9 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, each 9 gram of JIAOSANXIAN (Fructus Crataegi, Fructus Hordei Germinatus, Massa Medicata Fermentata), Poria 15 grams, Radix Ophiopogonis 9 grams, the Radix Paeoniae Alba 15 grams, Radix Angelicae Sinensis 15 grams, Herba Artemisiae Scopariae 9 grams, the Rhizoma Anemarrhenae 9 grams, Cortex Lycii 9 grams, Radix Glycyrrhizae 6 grams, Rhizoma Imperatae 6 grams, the Cortex Eucommiae 9 grams, Fructus Gardeniae 9 grams, Radix Scutellariae 15 grams, Squama Manis 6 grams, go up first 9 grams, first 9 being restrained into 216 grams.
CN99124959A 1999-12-30 1999-12-30 Chinese medicine powder preparation for curing leukemia Expired - Fee Related CN1077797C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN99124959A CN1077797C (en) 1999-12-30 1999-12-30 Chinese medicine powder preparation for curing leukemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN99124959A CN1077797C (en) 1999-12-30 1999-12-30 Chinese medicine powder preparation for curing leukemia

Publications (2)

Publication Number Publication Date
CN1262955A CN1262955A (en) 2000-08-16
CN1077797C true CN1077797C (en) 2002-01-16

Family

ID=5283673

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99124959A Expired - Fee Related CN1077797C (en) 1999-12-30 1999-12-30 Chinese medicine powder preparation for curing leukemia

Country Status (1)

Country Link
CN (1) CN1077797C (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1157166A (en) * 1996-01-25 1997-08-20 温顺明 Xuefukang medicine
CN1217188A (en) * 1997-11-12 1999-05-26 赵清涛 Chinese medicine Baixuekang and its production process
CN1238956A (en) * 1998-06-12 1999-12-22 许世平 Baixuekang for curing leukemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1157166A (en) * 1996-01-25 1997-08-20 温顺明 Xuefukang medicine
CN1217188A (en) * 1997-11-12 1999-05-26 赵清涛 Chinese medicine Baixuekang and its production process
CN1238956A (en) * 1998-06-12 1999-12-22 许世平 Baixuekang for curing leukemia

Also Published As

Publication number Publication date
CN1262955A (en) 2000-08-16

Similar Documents

Publication Publication Date Title
CN1062144C (en) Yisuishengxue chinese medicine preparation for tonifying marrow and promoting generation of blood
CN1562160A (en) Composite medicine for treating hepatitis B complication
CN1062157C (en) Hepatitis B curing toxin-dissipating pill
CN1131053C (en) Chinese medicine for treating diabetes
CN101670011A (en) Medicament for treating rheumatism and rheumatoid and preparation method thereof
CN102357211B (en) Traditional Chinese medicine composition for curing cancers
CN1879841A (en) A Chinese medicine for treating leukemia
CN1140064A (en) Formula and producing method for lactogenic finger citron oral preparation
CN101167932A (en) Traditional Chinese medicine for treating chronic hepatitis B
CN1082376C (en) Pathogenic factor eliminating and healthy energy supporting anticancer medicine
CN112891485B (en) Traditional Chinese medicine composition for treating neocoronary pneumonia
CN1077797C (en) Chinese medicine powder preparation for curing leukemia
CN1293908C (en) Cancer preventing and curing Chinese medicine of two snakes and Ganoderma Lucidum seu Japonicum
CN1385191A (en) Medicine for treating liver disease
CN100396300C (en) Chinese traditional medicine for treating enteritis and appendicitis, and method for preparing same
CN103071079B (en) Traditional Chinese medicinal composition for treating prurigo nodularis
CN104435545A (en) Traditional Chinese medicine preparation for treating leucopenia caused by benzene poisoning
CN101703660B (en) Anti-aging medicament
CN1052914C (en) Suyuwan pill for curing leucoderma
CN111759940B (en) Pharmaceutical composition for treating sicca syndrome and preparation method and application thereof
CN102727749B (en) Medicine for treating aplastic anemia
CN1562229A (en) Formula of Chinese herbal medicine decoction distinguished from males and females and combined with Western medicine for curing hepatitis B
CN111214584B (en) Traditional Chinese medicine composition for tonifying kidney and benefiting liver as well as preparation method and application thereof
CN100457177C (en) Chinese medicinal health-care preparation for cloaring lung, supplementing kidney
CN105770815A (en) Folium artemisiae argyi-containing traditional Chinese medicine composition for treating postpartum collapse and preparation method thereof

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee